Expression of Cytochrome P450 in non-small cell lung cancer

Tsunehiro Oyama, Kenji Sugio, Toyohi Isse, Akiko Matsumoto, Naohiro Nose, Hidetaka Uramoto, Tadahiro Nozoe, Masaru Morita, Norio Kagawa, Toshihiro Osaki, Manabu Muto, Kosei Yasumoto, Toshihiro Kawamoto

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Lung cancer accounts for most of cancer-related deaths in both men and women. Lung cancer is also associated with cigarette smoking that exposes the individual to carcinogenic chemicals. Normally, CYP enzymes (cytochrome P450s) metabolize carcinogens to inactive derivatives, however, occasionally the action of CYP enzymes leads to development of more potent carcinogens. In addition to the metabolism of carcinogenic compounds, CYP enzymes are also involved in the activation and/or inactivation of agents, which are used in the treatment of lung cancer. Therefore, the local level of CYP enzymes in lung cancer and surrounding tissues could be an important determinant in the efficacy of anticancer drugs. Furthermore, the expression of CYP19 (aromatase), estrogen synthesis P450, was found in more than 80% of non-small cell lung cancers. Lung cancer was also found to frequently express CYP24A1 that converts 1 alpha, 25-dihydroxyvitamin D3 to its inactive 24-hydroxylated derivatives. The understanding of the local expression of CYP enzymes in tumor tissues is important in the development of better treatment for lung cancer and a standardized treatment, tailor-made, for individual patients.

Original languageEnglish
Pages (from-to)5787-5793
Number of pages7
JournalFrontiers in Bioscience
Volume13
Issue number15
DOIs
Publication statusPublished - May 1 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Cytochrome P-450 Enzyme System
Lung Neoplasms
Cells
Enzymes
Aromatase
Carcinogens
Tissue
Derivatives
Calcitriol
Cytochromes
Metabolism
Tobacco Products
Tumors
Estrogens
Chemical activation
Neoplasms
Therapeutics
Smoking
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Oyama, T., Sugio, K., Isse, T., Matsumoto, A., Nose, N., Uramoto, H., ... Kawamoto, T. (2008). Expression of Cytochrome P450 in non-small cell lung cancer. Frontiers in Bioscience, 13(15), 5787-5793. https://doi.org/10.2741/3116

Expression of Cytochrome P450 in non-small cell lung cancer. / Oyama, Tsunehiro; Sugio, Kenji; Isse, Toyohi; Matsumoto, Akiko; Nose, Naohiro; Uramoto, Hidetaka; Nozoe, Tadahiro; Morita, Masaru; Kagawa, Norio; Osaki, Toshihiro; Muto, Manabu; Yasumoto, Kosei; Kawamoto, Toshihiro.

In: Frontiers in Bioscience, Vol. 13, No. 15, 01.05.2008, p. 5787-5793.

Research output: Contribution to journalArticle

Oyama, T, Sugio, K, Isse, T, Matsumoto, A, Nose, N, Uramoto, H, Nozoe, T, Morita, M, Kagawa, N, Osaki, T, Muto, M, Yasumoto, K & Kawamoto, T 2008, 'Expression of Cytochrome P450 in non-small cell lung cancer', Frontiers in Bioscience, vol. 13, no. 15, pp. 5787-5793. https://doi.org/10.2741/3116
Oyama T, Sugio K, Isse T, Matsumoto A, Nose N, Uramoto H et al. Expression of Cytochrome P450 in non-small cell lung cancer. Frontiers in Bioscience. 2008 May 1;13(15):5787-5793. https://doi.org/10.2741/3116
Oyama, Tsunehiro ; Sugio, Kenji ; Isse, Toyohi ; Matsumoto, Akiko ; Nose, Naohiro ; Uramoto, Hidetaka ; Nozoe, Tadahiro ; Morita, Masaru ; Kagawa, Norio ; Osaki, Toshihiro ; Muto, Manabu ; Yasumoto, Kosei ; Kawamoto, Toshihiro. / Expression of Cytochrome P450 in non-small cell lung cancer. In: Frontiers in Bioscience. 2008 ; Vol. 13, No. 15. pp. 5787-5793.
@article{a117042f972c402e9b1ba801fa9056fa,
title = "Expression of Cytochrome P450 in non-small cell lung cancer",
abstract = "Lung cancer accounts for most of cancer-related deaths in both men and women. Lung cancer is also associated with cigarette smoking that exposes the individual to carcinogenic chemicals. Normally, CYP enzymes (cytochrome P450s) metabolize carcinogens to inactive derivatives, however, occasionally the action of CYP enzymes leads to development of more potent carcinogens. In addition to the metabolism of carcinogenic compounds, CYP enzymes are also involved in the activation and/or inactivation of agents, which are used in the treatment of lung cancer. Therefore, the local level of CYP enzymes in lung cancer and surrounding tissues could be an important determinant in the efficacy of anticancer drugs. Furthermore, the expression of CYP19 (aromatase), estrogen synthesis P450, was found in more than 80{\%} of non-small cell lung cancers. Lung cancer was also found to frequently express CYP24A1 that converts 1 alpha, 25-dihydroxyvitamin D3 to its inactive 24-hydroxylated derivatives. The understanding of the local expression of CYP enzymes in tumor tissues is important in the development of better treatment for lung cancer and a standardized treatment, tailor-made, for individual patients.",
author = "Tsunehiro Oyama and Kenji Sugio and Toyohi Isse and Akiko Matsumoto and Naohiro Nose and Hidetaka Uramoto and Tadahiro Nozoe and Masaru Morita and Norio Kagawa and Toshihiro Osaki and Manabu Muto and Kosei Yasumoto and Toshihiro Kawamoto",
year = "2008",
month = "5",
day = "1",
doi = "10.2741/3116",
language = "English",
volume = "13",
pages = "5787--5793",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "15",

}

TY - JOUR

T1 - Expression of Cytochrome P450 in non-small cell lung cancer

AU - Oyama, Tsunehiro

AU - Sugio, Kenji

AU - Isse, Toyohi

AU - Matsumoto, Akiko

AU - Nose, Naohiro

AU - Uramoto, Hidetaka

AU - Nozoe, Tadahiro

AU - Morita, Masaru

AU - Kagawa, Norio

AU - Osaki, Toshihiro

AU - Muto, Manabu

AU - Yasumoto, Kosei

AU - Kawamoto, Toshihiro

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Lung cancer accounts for most of cancer-related deaths in both men and women. Lung cancer is also associated with cigarette smoking that exposes the individual to carcinogenic chemicals. Normally, CYP enzymes (cytochrome P450s) metabolize carcinogens to inactive derivatives, however, occasionally the action of CYP enzymes leads to development of more potent carcinogens. In addition to the metabolism of carcinogenic compounds, CYP enzymes are also involved in the activation and/or inactivation of agents, which are used in the treatment of lung cancer. Therefore, the local level of CYP enzymes in lung cancer and surrounding tissues could be an important determinant in the efficacy of anticancer drugs. Furthermore, the expression of CYP19 (aromatase), estrogen synthesis P450, was found in more than 80% of non-small cell lung cancers. Lung cancer was also found to frequently express CYP24A1 that converts 1 alpha, 25-dihydroxyvitamin D3 to its inactive 24-hydroxylated derivatives. The understanding of the local expression of CYP enzymes in tumor tissues is important in the development of better treatment for lung cancer and a standardized treatment, tailor-made, for individual patients.

AB - Lung cancer accounts for most of cancer-related deaths in both men and women. Lung cancer is also associated with cigarette smoking that exposes the individual to carcinogenic chemicals. Normally, CYP enzymes (cytochrome P450s) metabolize carcinogens to inactive derivatives, however, occasionally the action of CYP enzymes leads to development of more potent carcinogens. In addition to the metabolism of carcinogenic compounds, CYP enzymes are also involved in the activation and/or inactivation of agents, which are used in the treatment of lung cancer. Therefore, the local level of CYP enzymes in lung cancer and surrounding tissues could be an important determinant in the efficacy of anticancer drugs. Furthermore, the expression of CYP19 (aromatase), estrogen synthesis P450, was found in more than 80% of non-small cell lung cancers. Lung cancer was also found to frequently express CYP24A1 that converts 1 alpha, 25-dihydroxyvitamin D3 to its inactive 24-hydroxylated derivatives. The understanding of the local expression of CYP enzymes in tumor tissues is important in the development of better treatment for lung cancer and a standardized treatment, tailor-made, for individual patients.

UR - http://www.scopus.com/inward/record.url?scp=44649131477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649131477&partnerID=8YFLogxK

U2 - 10.2741/3116

DO - 10.2741/3116

M3 - Article

C2 - 18508622

AN - SCOPUS:44649131477

VL - 13

SP - 5787

EP - 5793

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 15

ER -